Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AKNE-MYCIN vs BACTROBAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Erythromycin, a macrolide antibiotic, binds to the 50S subunit of bacterial ribosomes and inhibits protein synthesis by blocking translocation of peptidyl-t RNA. Topically, it reduces Propionibacterium acnes colonization and exhibits anti-inflammatory properties.
Binds to isoleucyl-t RNA synthetase, inhibiting bacterial protein synthesis.
Topical treatment of acne vulgaris
Impetigo due to Staphylococcus aureus and Streptococcus pyogenes,Mupirocin-sensitive infections
Topical application of 2% solution twice daily to affected areas.
Mupirocin (Bactroban) 2% ointment or cream applied topically to affected area three times daily for 5 to 14 days. For intranasal use: 0.5 g of 2% ointment applied to each nostril twice daily for 5 days.
2-3 hours (normal renal function); up to 24-36 hours in severe renal impairment
Terminal elimination half-life: 1-1.5 hours in adults with normal renal function; prolonged in renal impairment (up to 30 hours in end-stage renal disease)
Not systemically absorbed to a clinically significant degree after topical application. If absorbed, erythromycin is primarily metabolized by hepatic cytochrome P450 enzymes, mainly CYP3A4.
Minimal systemic absorption; rapidly metabolized to monic acid (inactive) in skin and systemically.
Primarily renal (60-80% unchanged); minor biliary/fecal (15-30%)
Renal (90-95% unchanged), with minor biliary/fecal elimination (<5%)
Bound primarily to albumin (10-20%)
95% bound, primarily to albumin
0.2-0.3 L/kg, indicating limited extravascular distribution (primarily extracellular fluid)
0.15-0.3 L/kg, indicating distribution primarily into extracellular fluid
Topical: 2-5% (minimal systemic absorption); oral: 75-85%
Topical: Negligible systemic absorption (<0.05% after topical application to intact skin; slightly higher (up to 1%) on abraded skin; intranasal: <0.1%
No dosage adjustment required for topical use; systemic absorption negligible.
No dosage adjustment necessary for topical application. For intranasal use, no adjustment required. Systemic absorption is minimal.
No dosage adjustment required for topical use; systemic absorption negligible.
No dosage adjustment necessary for topical or intranasal use. Systemic absorption is minimal.
Safety and efficacy not established in children under 12 years; for age ≥12 years, same as adult dosing.
Children 3 months and older: Same as adult dosing. Topical: apply 2% ointment/cream three times daily for 5 to 14 days. Intranasal: apply 0.5 g of 2% ointment to each nostril twice daily for 5 days.
No specific adjustments; use with caution due to potential increased skin sensitivity.
No specific adjustments required. Use same dosing as adults. Caution in patients with renal impairment due to potential accumulation of polyethylene glycol vehicle with extensive use on open wounds or burns.
None
None.
For external use only; avoid contact with eyes, mouth, and mucous membranes. May cause skin irritation, burning, stinging, or dryness. Reported cases of pseudomembranous colitis with topical use (rare). Use with caution in patients with hepatic impairment if significant systemic absorption occurs. Cross-resistance with other macrolides may develop. Use during pregnancy only if clearly needed (category B).
Severe allergic reactions including anaphylaxis and angioedema; potential for superinfection with prolonged use; not for intranasal use except specific formulations.
Hypersensitivity to erythromycin or any component of the formulation. Concurrent use with pimozide or ergot alkaloids (potential for QT prolongation and ergotism, though systemic absorption low).
Known hypersensitivity to mupirocin or any component of the formulation.
No specific food interactions. Take with or without food. Avoid excessive intake of spicy or greasy foods, which may exacerbate acne.
No known food interactions. The drug is applied topically; oral intake does not affect its action.
Akne-Mycin (erythromycin topical) is Pregnancy Category B. No evidence of teratogenicity in animal studies; adequate human studies are lacking. Systemic absorption is minimal with topical use, but risk cannot be completely excluded. First trimester: low risk, but use only if clearly needed. Second and third trimesters: generally considered safe with minimal systemic exposure.
No evidence of teratogenicity in animal studies; limited human data; FDA Pregnancy Category B. Use only if clearly needed.
Erythromycin is excreted in human milk in small amounts. Topical Akne-Mycin results in negligible systemic absorption, making significant infant exposure unlikely. M/P ratio not reported for topical use; oral erythromycin M/P ratio is approximately 0.5. Caution is advised, but use is generally compatible with breastfeeding.
Unknown if excreted in human milk; caution advised. M/P ratio not established.
No dose adjustment necessary. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) are not clinically relevant for topical Akne-Mycin due to minimal systemic absorption. Apply as directed regardless of pregnancy trimester.
No dose adjustments recommended; systemic absorption is minimal.
Akne-Mycin (erythromycin topical) is effective for mild to moderate acne vulgaris. It can be combined with benzoyl peroxide to reduce antibiotic resistance. Avoid use with other topical erythromycin products to prevent overuse. Monitor for local skin reactions like erythema, scaling, or itching.
BACTROBAN (mupirocin) is a topical antibiotic effective against methicillin-resistant Staphylococcus aureus (MRSA) and Streptococcus pyogenes. It is contraindicated for use on burns or large open wounds due to risk of polyethylene glycol absorption. For impetigo, apply to affected area three times daily for 5-10 days. Not effective against fungal, viral, or anaerobic infections. Monitor for local irritation; discontinue if severe. Use intranasal formulation (BACTROBAN Nasal) for MRSA decolonization.
Apply a thin layer to affected areas once or twice daily as directed.,Wash skin gently with mild soap and pat dry before application.,Avoid contact with eyes, mouth, and mucous membranes.,Do not use more often than prescribed; overuse can increase irritation.,Inform your doctor if you develop severe redness, peeling, or discomfort.,Use sunscreen daily as this medication may increase sun sensitivity.
Apply a small amount of ointment to the affected area 3 times daily, or as directed.,Wash hands before and after application to prevent spreading infection.,Do not use on large areas of broken skin or deep wounds without medical advice.,Avoid contact with eyes and mucous membranes.,Complete the full course of treatment even if symptoms improve.,Stop use and contact doctor if rash or irritation occurs.,Do not share this medication with others.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AKNE-MYCIN vs BACTROBAN, answered by our medical review team.
AKNE-MYCIN is a Topical Antibiotic that works by Erythromycin, a macrolide antibiotic, binds to the 50S subunit of bacterial ribosomes and inhibits protein synthesis by blocking translocation of peptidyl-t RNA. Topically, it reduces Propionibacterium acnes colonization and exhibits anti-inflammatory properties.. BACTROBAN is a Topical Antibiotic that works by Binds to isoleucyl-t RNA synthetase, inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AKNE-MYCIN and BACTROBAN depend on the specific clinical indication. These are both Topical Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AKNE-MYCIN is: Topical application of 2% solution twice daily to affected areas.. The standard adult dose of BACTROBAN is: Mupirocin (Bactroban) 2% ointment or cream applied topically to affected area three times daily for 5 to 14 days. For intranasal use: 0.5 g of 2% ointment applied to each nostril twice daily for 5 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AKNE-MYCIN and BACTROBAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AKNE-MYCIN is classified as Category C. Akne-Mycin (erythromycin topical) is Pregnancy Category B. No evidence of teratogenicity in animal studies; adequate human studies are lacking. Systemic absorption is minimal with . BACTROBAN is classified as Category C. No evidence of teratogenicity in animal studies; limited human data; FDA Pregnancy Category B. Use only if clearly needed.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.